Reliable Quality

Affordable Innovation

Research Progress

At present, Henlius has launched 5 products and 23 indications, and 3 marketing applications have been accepted for review in China and the EU, respectively.  Meanwhile, Henlius has conducted over 30 clinical studies for 16 products globally. HANLIKANG  (rituximab injection), the first product of Henlius, has been approved by the National Medical Products Administration (NMPA) as China's first biosimilar. The second product HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe) is a Chinese mAb biosimilar approved in the U.S. the EU and China, bringing more treatment options to patients with HER2 positive breast and gastric cancer worldwide. In March 2022, the company’s first self-developed innovative monoclonal antibody HANSIZHUANG (serplulimab injection), was launched. It has been approved by the NMPA for the treatment of Microsatellite Instability-High (MSI-H) solid tumors and squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC).

Clinical-stage Products
Generic Name
Study Phase
Potential Indication
Study Phase
Product Pipeline

With the efficient and innovative in-house capabilities, Henlius has developed a diversified and advanced drug pipeline with a focus in the fields of oncology, autoimmune diseases etc.